Rubius Therapeutics

Rubius Therapeutics

Rubius Therapeutics is a biotechnology company using stem cells to develop red blood cell cellular therapies.

Rubius Therapeutics is a biotechnology company using stem cells to develop red blood cell cellular therapies that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Avak Kahvejian.

The company is primarily interested in creating life-changing, allogenic cellular therapies for patients with severe diseases. They have developed a proprietary RED PLATFORM to generate red blood cells and genetically engineer them into a new class of cellular medicines. The platform harnesses properties of red blood cells and the genetic engineering to deliver their promise of cellular therapy as a solution to diseases and treatments of those diseases.

The company expresses biotherapeutic proteins within or on their cell surface to create selective, potent, allogenic cellular medicines aimed at treating a range of diseases. This can potentially be used to kill tumors in cancer as well as regulate the immune system in order to treat autoimmune diseases. The leveraging of distinct therapeutic modalities includes immune system activation and tolerance induction.

Funding

Series A

On December 9, 2015 Rubius Therapeutics announced completing their series A funding round with $25 million in funding from Flagship Pioneering.

Series B

On June 21, 2017 Rubius Therapeutics completed their series B funding round with $120 million in funding from Flagship Pioneering.

Series C

On March 1, 2018 Rubius Therapeutics closed their series C funding round with $100 million in funding from Flagship Pioneering and 26 other participating investors.

Timeline

March 1, 2018

Series C funding round

On March 1, 2018 Rubius Therapeutics closed their series C funding round with $100 million in funding from Flagship Pioneering and 26 other participating investors.

June 21, 2017

Series B funding round

On June 21, 2017 Rubius Therapeutics completed their series B funding round with $120 million in funding from Flagship Pioneering.

December 12, 2015

Series A funding round

On December 9, 2015 Rubius Therapeutics announced completing their series A funding round with $25 million in funding from Flagship Pioneering.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria

Rubius Therapeutics

Web

Documentaries, videos and podcasts

Title
Date
Link

Rubius Therapeutics

October 23, 2017

Rubius Therapeutics: Pioneering a New Era of Cellular Therapies

November 15, 2015

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Bram Berkowitz
June 16, 2020
AmericanInno
"Amazing talent is available to build a strong team and operate a biotech facility in Rhode Island."
BioSpace
May 15, 2020
BioSpace
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company plans to present preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers, during the American Association f
BioSpace
May 12, 2020
BioSpace
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being he

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.